FDA Opens Comment Period on GenAI Device Regulation - Medical Device and Diagnostic industry
Reported by Medical Device and Diagnostic industry · all stories from mddionline.com
Editorial digest
The U.S. Food and Drug Administration has opened a period for public comments regarding the regulation of generative artificial intelligence in medical devices.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at Medical Device and Diagnostic industry →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/22/2026
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
Federal regulators have completed formal guidelines for software applications paired with medications, drawing positive reactions from pharmaceutical manufacturers.
- Trusted health newsroom10/22/2026
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Virtual clinics are providing off-label GLP-1 therapies for substance use disorders before receiving formal regulatory authorization.
- Trusted health newsroom10/6/2026
STAT+: FDA spells out 2027 AI guidance plans
The FDA has detailed its plans for AI guidelines in 2027.
- Trusted health newsroom10/7/2026
STAT+: Why health AI pilots in Utah may be on a collision course with the FDA
Utah's healthcare artificial intelligence trials may conflict with federal regulatory bodies.
- Trusted health newsroom8/20/2026
FDA weighs regulatory approach for genAI medical devices - MobiHealthNews
The FDA is deliberating its regulatory strategy for generative AI medical devices.
- Reputable trade press8/20/2026
FDA considers ‘competency-based’ evaluations for GenAI-enabled medical devices - MassDevice
The FDA is considering 'competency-based' evaluations for generative AI medical devices.